Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Novel neuroprotective strategies in ischemic retinal lesions Szabadfi K; Mester L; Reglodi D; Kiss P; Babai N; Racz B; Kovacs K; Szabo A; Tamas A; Gabriel R; Atlasz TInt J Mol Sci 2010[Feb]; 11 (2): 544-561Retinal ischemia can be effectively modeled by permanent bilateral common carotid artery occlusion, which leads to chronic hypoperfusion-induced degeneration in the entire rat retina. The complex pathways leading to retinal cell death offer a complex approach of neuroprotective strategies. In the present review we summarize recent findings with different neuroprotective candidate molecules. We describe the protective effects of intravitreal treatment with: (i) urocortin 2; (ii) a mitochondrial ATP-sensitive K(+) channel opener, diazoxide; (iii) a neurotrophic factor, pituitary adenylate cyclase activating polypeptide; and (iv) a novel poly(ADP-ribose) polymerase inhibitor (HO3089). The retinoprotective effects are demonstrated with morphological description and effects on apoptotic pathways using molecular biological techniques.|Animals[MESH]|Benzimidazoles/therapeutic use[MESH]|Diazoxide/therapeutic use[MESH]|Disease Models, Animal[MESH]|Ischemia/drug therapy/pathology[MESH]|Neuroprotective Agents/*therapeutic use[MESH]|Pituitary Adenylate Cyclase-Activating Polypeptide/therapeutic use[MESH]|Retinal Artery Occlusion/*drug therapy/pathology[MESH]|Urocortins/therapeutic use[MESH] |